bendamustine hydrochloride has been researched along with Brill-Symmers Disease in 106 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (9.43) | 29.6817 |
| 2010's | 52 (49.06) | 24.3611 |
| 2020's | 44 (41.51) | 2.80 |
| Authors | Studies |
|---|---|
| Leslie, LA | 1 |
| Ashida, T; Espinoza, JL; Haeno, T; Hanamoto, H; Hirase, C; Inoue, H; Kumode, T; Maeda, Y; Matsuda, M; Matsumura, I; Morita, Y; Nishio, K; Rai, S; Sakai, K; Serizawa, K; Tanaka, H; Taniguchi, Y; Tatsumi, Y; Watatani, Y | 1 |
| Hirakawa, Y; Iwai, T; Kitamura, Y; Kuriyama, K; Matsumoto, Y; Nagata, H; Nishikawa, R; Ohshiro, M; Sugitani, M; Tsuji, T; Uchiyama, H | 1 |
| Cahill, KE; Smith, SM | 1 |
| Fujimura, T; Harada, N; Kawasaki, N; Kondoh, O; Yamashita-Kashima, Y; Yoshimura, Y; Yoshiura, S | 1 |
| Fujimura, T; Harada, N; Kawasaki, N; Kondoh, O; Kurasawa, M; Yamashita-Kashima, Y; Yorozu, K; Yoshimura, Y; Yoshiura, S | 1 |
| Choi, I; Hirata, A; Hirata, K; Miyashita, K; Nakashima, E; Narazaki, T; Ohno, H; Suehiro, Y; Tachikawa, Y; Taguchi, K; Tanaka, T; Utsunomiya, H | 1 |
| Burke, JM; Diefenbach, C; Ferrari, S; Gilbertson, M; Khan, C; Nielsen, TG; Raval, A; Sellam, G; Sharman, JP; Shivhare, M; Tani, M; Ujjani, C; Vitolo, U; Younes, A; Yuen, S | 1 |
| Ennishi, D; Fujii, S; Fujiwara, Y; Hiramatsu, Y; Imai, T; Maeda, Y; Nawa, Y; Niiya, D; Sunami, K; Urata, T; Yano, T; Yoshida, I | 1 |
| Asakura, S; Saito, T; Ueda, Y; Wada, S; Yano, T | 1 |
| Cheng, LL; Cheng, S; Wang, L; Xu, PP; Zhang, MC; Zhao, F; Zhao, WL; Zheng, Z | 1 |
| Bastos Oreiro, M; Buño, I; Carbonell, D; Chicano, M; Díaz Crespo, FJ; Diez Martín, JL; Kwon, M; Martín Rojas, R; Martínez-Laperche, C; Menárguez, J; Muñiz, P; Sanz-Villanueva, L; Suárez-González, J | 1 |
| Kameoka, Y | 1 |
| Honda, A; Kurokawa, M; Maki, H; Masamoto, Y; Shimura, A; Taoka, K | 1 |
| Alhaj Moustafa, M; Borah, BJ; Cerhan, JR; Dholakia, R; Hoppe, BS; Jiang, L; Li, K; Moriarty, JP; Peterson, J; Tun, HW; Witzig, TE | 1 |
| Ishio, T; Izumiyama, K; Kobayashi, M; Kondo, T; Mori, A; Morioka, M; Muraki, H; Saito, M; Tsukamoto, S; Yokoyama, E | 1 |
| Bedini, A; Bettelli, F; Dolci, G; Franceschini, E; Fregni-Serpini, G; Grottola, A; Guaraldi, G; Luppi, M; Meschiari, M; Mussini, C; Pecorari, M; Pellegrino, M; Perno, CF; Sarti, M; Todisco, V | 1 |
| Ballerini, F; Bari, A; Califano, C; Capponi, M; Catellani, H; Conconi, A; Federico, M; Galimberti, S; Ghiggi, C; Gini, G; Liberati, AM; Luminari, S; Manni, M; Mannina, D; Marcheselli, L; Massaia, M; Merli, M; Musto, P; Musuraca, G; Nizzoli, ME; Pastore, D; Pennese, E; Perrone, T; Pulsoni, A; Re, F; Skrypets, T; Stefani, PM; Usai, SV; Vitolo, U | 1 |
| Abadi, U; Aumann, S; Aviv, A; Berger, T; Gafter-Gvili, A; Goldschmidt, N; Gurion, R; Harel, R; Horesh, N; Nachmias, B; Raanani, P; Shimony, S; Shmerts, E; Shochat, T | 1 |
| Choi, HJ; Jo, JC; Lee, YJ; Park, SH; Seo, M | 1 |
| Abe, M; Haruyama, T; Honda, S; Itani, K; Iwanaga, M; Kohno, K; Moroga, Y; Nakayama, T; Ogata, M; Ohtsuka, E; Okuhiro, K; Ono, K; Saburi, M; Sasaki, H; Takano, K; Yanai, Y; Yoshida, N | 1 |
| Caces, DB; Curtis, M; Danielewicz, I; Freeman, J; García-Sancho, AM; Glazunova, V; Grigg, A; Henninger, T; Hess, G; Hou, JZ; Janssens, A; Kim, SJ; Masliak, Z; McKay, P; Merli, F; Munakata, W; Nagai, H; Nastoupil, LJ; Özcan, M; Pavlovsky, MA; Preis, M; Qin, R; Rowe, M; Salles, G; Tamegnon, M; Thieblemont, C; Wang, T | 1 |
| Chen, W; Gong, Q; Ma, J; Xia, Y; Zhao, D; Zhen, B | 1 |
| Belada, D; Cheson, BD; Fingerle-Rowson, G; Gribben, J; Harbron, C; Hoster, E; Kahl, B; Kehden, B; Mundt, K; Nicolas-Virelizier, E; Pott, C; Sehn, LH; Spielewoy, N; Wassner-Fritsch, E | 1 |
| Caballero, MD; Canales, M; Capote, FJ; Durán, S; Giraldo, P; Gutiérrez, A; López, A; Márquez, JA; Martín, A; Montalbán, C; Peñalver, FJ; Ramírez, MJ; Rodríguez-Caravaca, G; Salar, A; Sánchez, B; Sancho, JM; Terol, MJ | 1 |
| Bellesi, S; Cuccaro, A; D'Alò, F; De Stefano, V; Hohaus, S; Leccisotti, L; Macis, G; Maiolo, E; Malafronte, R; Modoni, A; Mores, N; Piludu, F | 1 |
| Ito, S; Izumiyama, K; Kakinoki, Y; Kondo, T; Shimono, J; Teshima, T; Tsutsmi, Y | 1 |
| Advani, RH; Ansell, SM; Cescon, TP; Chang, JE; Cheema, PS; Dy, PA; Evens, AM; Gascoyne, RD; Habermann, TM; Hong, F; Kahl, BS; O'Brien, TE; Quon, A; Ranheim, EA; Winter, JN; Witzig, TE | 1 |
| Jaksic, O; Lucijanic, M | 1 |
| Böttcher, S; Hauf, E; Herold, M; Hirt, C; Kahl, C; Kämpfe, D; Keller, U; Klapper, W; Koch, K; Kroschinsky, F; La Rosée, P; Marks, R; Maschmeyer, G; Meissner, J; Meyer, A; Monecke, A; Pouyiourou, M; Prange-Krex, G; Schmalenberg, H; Scholz, CW; Stroux, A; Viardot, A; Vucinic, V; Weber, T; Witzens-Harig, M | 1 |
| Arthur, C; Crump, M; Fleury, I; Flinn, IW; Gritti, G; Hiddemann, W; Humphrey, K; Kornacker, M; Le Dû, K; Mobasher, M; Petrich, A; Pro, B; Punnoose, EA; Rusconi, C; Samineni, D; Sinha, A; Spielewoy, N; Szafer-Glusman, E; Topp, MS; Yuen, SLS; Zinzani, PL | 1 |
| Cerchione, C; Cimmino, I; De Renzo, A; Lucchesi, A; Martinelli, G; Musuraca, G; Nappi, D; Pane, F | 1 |
| Choi, I; Hatta, Y; Iino, M; Kakinoki, Y; Kanno, M; Kitazume, K; Maeda, Y; Masaki, Y; Masunari, T; Miura, K; Nakamura, S; Suzuki, R; Takizawa, J; Tamura, S; Tsujimura, H; Yagi, H; Yamamoto, K; Yoshida, A; Yoshida, I; Yoshida, T; Yoshino, T | 1 |
| Cerchione, C; Della Pepa, R; Giordano, C; Leone, A; Pane, F; Picardi, M; Pugliese, N; Vitiello, S | 1 |
| Fowler, N | 1 |
| Hamada, R; Matsumura, T; Sakai, K; Takahashi, T; Tominaga, T | 1 |
| Iwasaki, H; Kadowaki, M; Matsushima, T; Minami, M; Takase, K; Yamasaki, S | 1 |
| Cartron, G; Casasnovas, O; Dalban, C; Ghesquières, H; Hernandez, C; Jardin, F; Le Bras, F; Le Gouill, S; Metzger, S; Nicolas-Virelizier, E; Pérol, D; Vizoso, S | 1 |
| Baldini, L; Balzarotti, M; Boccomini, C; Bolis, S; Chiarenza, A; Ciccone, G; Corradini, P; Evangelista, A; Ferrero, S; Freilone, R; Ladetto, M; Marina Liberati, A; Nassi, L; Novo, M; Puccini, B; Rattotti, S; Rigacci, L; Rusconi, C; Stelitano, C; Tucci, A; Vitolo, U; Volpetti, S | 1 |
| Bolen, CR; Herold, M; Hiddemann, W; Huet, S; Klapper, W; Marcus, R; Mattiello, F; Mir, F; Nielsen, T; Oestergaard, MZ; Salles, G; Venstrom, JM; Weigert, O | 1 |
| Espinoza, JL; Haeno, T; Hanamoto, H; Hirase, C; Inoue, H; Kumode, T; Maeda, Y; Matsuda, M; Matsumura, I; Morita, Y; Rai, S; Tanaka, H; Tatsumi, Y; Wada, Y; Watatani, Y | 1 |
| Chiba, A; Honda, A; Kogure, Y; Kurokawa, M; Matsuda, K; Nakamura, F; Nakazaki, K; Takezaki, T; Toyama, K | 1 |
| Kahl, B | 1 |
| Kurokawa, M; Masamoto, Y; Shimura, A | 1 |
| Barreto, JN; Limper, AH; Mara, KC; Rice, ML; Thompson, CA; Tosh, PK | 1 |
| Abe, R; Amagai, M; Funakoshi, T; Kikuchi, T; Koda, Y; Kurihara, Y; Mori, T; Okamoto, S; Sato, H; Shimizu, T; Tsunoda, K; Yamagami, J | 1 |
| Alnuaimi, K; Lascoux-Combes, C; Lavolé, J; Mallet, V; Pol, S; Roque Afonso, AM; Sogni, P | 1 |
| Cerchione, C; Cuzzocrea, S; Ferrero, S; Mauro, E; Mian, M; Mondello, P; Nappi, D; Steiner, N; Willenbacher, W | 1 |
| Clowes, M; Cutting, R; Davis, S; Harnan, S; Pandor, A; Rafia, R; Sorour, Y; Stevens, JW | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Barbui, AM; Burciu, A; Canales, MA; Cannell, PK; Collins, GP; Dürig, J; Fingerle-Rowson, G; Forstpointner, R; Herold, M; Hertzberg, M; Hiddemann, W; Klanova, M; Marcus, RE; Nielsen, T; Radford, J; Seymour, JF; Tobinai, K; Trotman, J; Wolbers, M | 1 |
| Bernaards, C; Guzauskas, GF; Krivasi, T; Masaquel, A; Reyes, C; Veenstra, DL | 1 |
| Haukaas, FS; Krivasi, T; Ohna, A | 1 |
| Cheah, CY; Marlton, P; Opat, S; Trotman, J | 1 |
| Bautista, J; Gandhi, P; Rogers, A; Tang, J | 1 |
| Farris, M; Hughes, RT; Lamar, Z; Menke, JR; Ohgami, RS; Soike, MH; Winkfield, K | 1 |
| Aguiar, D; Alfaro, J; Alvarez, R; Blasco, A; Calvo, V; Casanova, M; de la Cruz Merino, L; García-Arroyo, FR; Herrero, J; Llanos, M; Martinez-Banaclocha, N; Provencio, M; Quero, C; Rodriguez-Abreu, D; Rueda, A | 1 |
| Alderuccio, JP; Becnel, MR; Caimi, P; Calzada, O; Cerhan, JR; Cohen, JB; Desai, A; Evens, AM; Fakhri, B; Ghosh, N; Goldman, ML; Habermann, TM; Hill, BT; Hussain, MJ; Jagadeesh, D; Kahl, BS; Kodali, A; Link, BK; Lossos, IS; Martin, P; Maurer, MJ; Mehra, P; Mukhija, D; Nastoupil, L; Portell, CA; Reddy, P; Smith, SD; Tiutan, T; Winter, AM | 1 |
| Dawson, K; Guzauskas, GF; Masaquel, A; Thuresson, PO; Veenstra, DL | 1 |
| Buchheit, V; Cartron, G; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Hargreaves, CE; Hiddemann, W; Jamois, C; Marcus, R; Meneses-Lorente, G; Sahin, D; Seymour, JF; Strefford, JC | 1 |
| Brewster, M; Buchheit, V; Fingerle-Rowson, G; Frey, N; Gibiansky, E; Gibiansky, L; Jamois, C | 1 |
| Anderson, S; Atkins, J; Bartlett, NL; Blum, KA; Cheson, BD; Christian, B; Dockter, TJ; Hsi, ED; Jung, SH; Leonard, JP; Polley, MY; Wagner-Johnston, N | 1 |
| Cafferty, F; Connors, JM; Farinha, P; Ferguson, D; Freeman, CL; Gerrie, AS; Kridel, R; Moccia, AA; Savage, KJ; Scott, DW; Sehn, LH; Skinnider, B; Slack, GW; Villa, DR | 1 |
| Cheson, BD; Ujjani, C | 1 |
| Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Hoki, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Okagawa, Y; Sakurai, T; Yamada, M | 1 |
| Atmar, J; Mullen, E | 1 |
| Fesler, MJ; Hyder, MA; Parker, SM | 1 |
| Ando, M; Emi, N; Inaguma, Y; Ito, K; Kakumae, Y; Okamoto, A; Okamoto, M; Tokuda, M; Yamada, S; Yanada, M | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Abe, H; Asano, H; Fukayama, M; Higo, T; Kurokawa, M; Miyagaki, T; Nakamura, F; Senda, N; Shinohara, A; Yoshizaki, A | 1 |
| Izutsu, K | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Atta, J; Buske, C; Dreyling, M; Hess, G; Keller, U; Kirschey, S; Klapper, W; Medler, C; Ruckes, C; Scholz, CW; Theobald, M; van Oordt, C; Witzens-Harig, M | 1 |
| Barth, J; Brugger, W; Bruns, I; Czibere, A; Fenk, R; Germing, U; Haas, R; Heil, G; Kobbe, G; Kofahl-Krause, D; Kronenwett, R; Losem, C; Maschmeyer, G; Niederle, N; Pechtel, S; Rummel, MJ; Schroeder, T; Welslau, M; Zohren, F | 1 |
| Chiba, S; Hasegawa, Y; Kurita, N; Maie, K; Muroi, K; Noguchi, M; Obara, N; Sakata-Yanagimoto, M; Sato, T; Yokoyama, Y | 1 |
| Cheah, CY; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neelapu, SS | 1 |
| Freedman, AS; Jacobson, CA | 1 |
| Collar, JM; López-Guillermo, A; Oyagüez, I; Rueda, A; Sabater, E; Salar, A | 1 |
| Centeno-Haro, M; Marí-Jimenez, P; Martínez-Losada, C; Perez-Seoane, C; Rodríguez-García, G; Sánchez-García, J | 1 |
| Hatake, K; Kusano, Y; Terui, Y; Yokoyama, M | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
| Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E | 1 |
| Ogura, M | 3 |
| Cheson, BD | 2 |
| Besses, C; Garcia, M; Salar, A; Sanchez-Gonzalez, B; Serrano, S | 1 |
| Friedberg, JW | 1 |
| Giné, E; Gutiérrez-García, G; López-Guillermo, A | 1 |
| Ghielmini, M | 1 |
| Agostinelli, C; Mannu, C; Piccaluga, PP; Pileri, SA; Sabattini, E; Sagramoso, C; Sapienza, MR; Zinzani, PL | 1 |
| Ishizawa, K; Ogura, M; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K | 1 |
| Gregory, SA; Rummel, MJ | 1 |
| Kersten, MJ; van Oers, MH | 1 |
| Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME | 1 |
| Hoot, A; Langevin, J; Lim, SH; Pathapati, S | 1 |
| Austein, T; Demme, B | 1 |
| Ganesan, P; Malipatil, B; Sagar, TG; Sundersingh, S | 1 |
| Asaka, M; Imamura, M; Miyashita, N; Ogasawara, R; Tanaka, J; Tsutsumi, Y | 1 |
| Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okikawa, Y | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L | 1 |
| Bremer, K | 1 |
| Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C | 1 |
| Aldaoud, A; Dreyling, M; Haak, U; Hess, G; Heymanns, J; Hiddemann, W; Huber, C; Köppler, H; Losem, C; Schmitz, S; Thomalla, J; Unterhalt, M; Weide, R | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Schneider, B; Seipelt, G; Sommerlad, WD; Weidmann, E | 1 |
21 review(s) available for bendamustine hydrochloride and Brill-Symmers Disease
| Article | Year |
|---|---|
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Follicular Lymphoma: a Focus on Current and Emerging Therapies
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine | 2022 |
High-risk follicular lymphoma: Treatment options.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Lymphoma, Follicular; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Survival Rate | 2021 |
Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance; Drug Therapy, Combination; Humans; Lymphoma, Follicular; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years; Rituximab; Technology Assessment, Biomedical | 2018 |
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Bendamustine Hydrochloride; Cyclophosphamide; Disease Management; Doxorubicin; Humans; Lymphoma, Follicular; Recurrence; Rituximab; Stem Cell Transplantation; Vincristine | 2019 |
Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Histiocytic Sarcoma; Humans; Lymphoma, Follicular; Male; Prognosis; Rituximab | 2019 |
The optimal management of follicular lymphoma: an evolving field.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisone; Prognosis; Rituximab; Vincristine | 2013 |
Norovirus in immunocompromised patients.
Topics: Abdominal Pain; Aged; Antibodies, Monoclonal, Murine-Derived; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Caliciviridae Infections; Combined Modality Therapy; Disinfection; Female; Fluid Therapy; Gastroenteritis; Hand Disinfection; Humans; Immunocompromised Host; Incidence; Infection Control; Lymphoma, Follicular; Mitoxantrone; Nitrogen Mustard Compounds; Norovirus; Rituximab; Virus Shedding | 2013 |
Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hepatitis C, Chronic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Cirrhosis; Lymphoma, B-Cell; Lymphoma, Follicular; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2013 |
[Management of follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consolidation Chemotherapy; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Predictive Value of Tests; Prednisolone; Prednisone; Prognosis; Rituximab; Vincristine | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Combined Modality Therapy; Humans; Lenalidomide; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2016 |
[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Gene Targeting; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Prednisone; Prognosis; Purine Nucleosides; Pyrimidinones; Risk; Rituximab; Salvage Therapy; Sirolimus; Transplantation, Autologous; Vincristine | 2008 |
Current immunochemotherapy strategies in follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Nitrogen Mustard Compounds; Prednisone; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Vidarabine; Vincristine | 2010 |
Follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Rituximab; Watchful Waiting | 2010 |
Biology and treatment of follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Nitrogen Mustard Compounds; Rituximab | 2009 |
Bendamustine's emerging role in the management of lymphoid malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2011 |
Treatment strategies in advanced stage follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Biomarkers; Disease-Free Survival; Drug Administration Schedule; Drug Therapy; Humans; Immunotherapy; Lymphoma, Follicular; Mice; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Rituximab; Secondary Prevention; Treatment Outcome; Tumor Microenvironment | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Recurrence; Vincristine; Waldenstrom Macroglobulinemia | 2012 |
[Recent therapeutic strategy for follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Design; Drug Therapy, Combination; Fludrocortisone; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Neoplasm Staging; Nitrogen Mustard Compounds; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Time Factors; Transplantation, Autologous; Treatment Outcome | 2007 |
25 trial(s) available for bendamustine hydrochloride and Brill-Symmers Disease
| Article | Year |
|---|---|
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine | 2023 |
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Piperidines; Prednisone; Rituximab; Vincristine | 2023 |
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy | 2019 |
Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Monocytes; Recurrence; Retrospective Studies | 2020 |
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Rituximab; Young Adult | 2020 |
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab; Sulfonamides | 2020 |
Consolidation with
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consolidation Chemotherapy; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab | 2021 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Etoposide; Humans; Lymphoma, Follicular; Melphalan; Prospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Mitoxantrone; Neoplasm Grading; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Safety; Topoisomerase II Inhibitors | 2021 |
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Vincristine; Young Adult | 2018 |
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; Female; Humans; Lymphoma, Follicular; Male; Medicare; Neoplasm Recurrence, Local; Progression-Free Survival; Quality-Adjusted Life Years; Rituximab; United States | 2018 |
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Spain | 2019 |
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Survival Rate; Vincristine | 2019 |
Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Costs; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Prognosis; Quality-Adjusted Life Years; Rituximab; Survival Rate; United States; Vincristine; Young Adult | 2019 |
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Body Weight; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Models, Biological; Prednisone; Progression-Free Survival; Sex Factors; Treatment Outcome; Vincristine | 2019 |
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Models, Biological; Progression-Free Survival; Rituximab | 2019 |
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Progression-Free Survival; Remission Induction | 2019 |
Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrogen Mustard Compounds; Prognosis; Prospective Studies; Remission Induction; Rituximab; Safety; Sirolimus; Survival Rate | 2015 |
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Oncogene Proteins, Fusion; Prednisone; Prognosis; Rituximab; Vincristine | 2015 |
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Communicable Diseases; Hematologic Diseases; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab | 2016 |
Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve | 2011 |
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2002 |
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
60 other study(ies) available for bendamustine hydrochloride and Brill-Symmers Disease
| Article | Year |
|---|---|
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Female; Gene Expression Profiling; Humans; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Lymphoma, Follicular; Male; Middle Aged; Mutation; Prognosis; Progression-Free Survival; Rituximab; T-Lymphocytes; Treatment Failure; Tumor Microenvironment | 2022 |
Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Bronchiolitis Obliterans; Female; Humans; Lymphoma, Follicular; Paraneoplastic Syndromes; Pemphigus | 2022 |
Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Prednisolone; Rituximab | 2022 |
Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Protein Serine-Threonine Kinases; Rituximab | 2022 |
Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoglobulin G; Lymphoma, Follicular; Nitrogen Mustard Compounds; Retrospective Studies; Rituximab | 2022 |
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gallium; Humans; Lymphoma, Follicular; Rituximab | 2022 |
Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hematology; Humans; Incidence; Leukopenia; Lymphoma, Follicular; Male; Retrospective Studies; Rituximab; Thrombocytopenia | 2022 |
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; COVID-19; Humans; Immunocompromised Host; Lymphoma, Follicular; Rituximab; SARS-CoV-2 | 2022 |
[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Chronic Disease; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Rituximab | 2022 |
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
Topics: Bendamustine Hydrochloride; Biomarkers; Cyclophosphamide; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Humans; Lymphoma, Follicular; Mutation; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2022 |
[Standard treatment and future perspectives for follicular lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab | 2022 |
Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Rituximab | 2023 |
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Topics: Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2023 |
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Bendamustine Hydrochloride; COVID-19; COVID-19 Vaccines; Humans; Immunity, Humoral; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2; Vaccination | 2023 |
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; COVID-19; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2 | 2023 |
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Febrile Neutropenia; Humans; Immunotherapy; Lymphoma, Follicular; Retrospective Studies; Rituximab | 2023 |
A Case of Adenomyosis Showing Size Reduction in a Follicular Lymphoma Patient Receiving Chemotherapy With R-Bendamustine.
Topics: Adenomyosis; Bendamustine Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Middle Aged; Positron Emission Tomography Computed Tomography | 2023 |
Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Rituximab | 2023 |
Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; East Asian People; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Quality of Life | 2023 |
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Rituximab | 2020 |
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Rituximab | 2020 |
Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Immunoglobulins, Intravenous; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Lymphopenia; Magnetic Resonance Imaging; Maintenance Chemotherapy; Middle Aged; Plasmapheresis; Prednisone; Recurrence; Rituximab; Vincristine | 2020 |
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Prednisone; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2020 |
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Rituximab; Vincristine | 2020 |
Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol. 2020; 105: 667-671".
Topics: Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Morbidity | 2021 |
BCL-2 inhibition in follicular lymphoma: can we tip the scales?
Topics: Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Follicular; Proto-Oncogene Proteins c-bcl-2; Rituximab; Sulfonamides | 2020 |
[Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma].
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Middle Aged; Thrombocytopenia | 2020 |
Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphopenia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rituximab | 2022 |
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Neoplasm Proteins; Prednisone; Prognosis; Risk; Rituximab; RNA, Neoplasm; Transcriptome; Vincristine | 2021 |
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Clinical Trials, Phase II as Topic; Disease Management; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Young Adult | 2021 |
Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Middle Aged; Rituximab | 2021 |
Reduced bendamustine for elderly patients with follicular lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies | 2022 |
Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Female; Humans; Incidence; Lymphoma, Follicular; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Polymerase Chain Reaction; Proportional Hazards Models; Retrospective Studies; Rituximab; Time Factors; Young Adult | 2021 |
Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lymphoma, Follicular; Neoplasm Grading; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Pemphigus; Radiodermatitis; Rituximab; Severity of Illness Index; Skin; Treatment Outcome; Tumor Burden | 2017 |
Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Chronic Disease; Drug Combinations; Fatal Outcome; Female; Hepatitis E; Humans; Lymphoma, Follicular; Rituximab | 2018 |
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Middle Aged; Neoplasm Grading; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Health Care Costs; Humans; Lymphoma, Follicular; Norway; Progression-Free Survival; Quality-Adjusted Life Years; Rituximab; Survival Analysis; Treatment Failure | 2018 |
Acquired Gitelman Syndrome Secondary to Bendamustine Use.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Gitelman Syndrome; Humans; Hypokalemia; Lymphoma, Follicular; Male; Middle Aged | 2018 |
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Disease Progression; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Rituximab; Young Adult | 2019 |
[Bendamustine-rituximab therapy is effective for transformed follicular lymphoma with significant expression of p53].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Rituximab; Tumor Suppressor Protein p53 | 2013 |
Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Female; Humans; Immune System; Lymphocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome | 2015 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Eruptions; Female; Humans; Lymphoma, Follicular; Nitrogen Mustard Compounds; Paraneoplastic Syndromes; Pemphigus; Recurrence; Rituximab; Salvage Therapy | 2015 |
Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Lymphoma, Follicular; Middle Aged; Rituximab | 2015 |
Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Costs and Cost Analysis; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma, Follicular; Markov Chains; Prednisone; Quality-Adjusted Life Years; Rituximab; Spain; Vincristine | 2016 |
A rare composite lymphoma: follicular and in situ mantle cell.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Composite Lymphoma; Female; Humans; Lymph Nodes; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Remission Induction; Rituximab; Treatment Outcome | 2016 |
Lichenoid drug eruption associated with Bendamustine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Eruptions; Humans; Lichenoid Eruptions; Lymphoma, Follicular; Male; Recurrence; Rituximab; Salvage Therapy | 2016 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Monitoring; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Survival Analysis; Treatment Outcome; Tumor Burden; Vincristine | 2017 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53.
Topics: Aged; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Tumor Suppressor Protein p53 | 2009 |
The emerging role of bendamustine in follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Nitrogen Mustard Compounds; Rituximab | 2009 |
Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cytomegalovirus Infections; Female; Gastritis; Humans; Lymphoma, Follicular; Nitrogen Mustard Compounds; Virus Activation | 2012 |
Uncommon recurrence of follicular lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Head and Neck Neoplasms; Humans; Lymphoma, Follicular; Male; Nitrogen Mustard Compounds; Prednisone; Remission Induction; Rituximab; Skin Neoplasms | 2012 |
Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Therapy, Combination; Exanthema; Female; Humans; India; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisolone; Retrospective Studies; Rituximab; Vincristine | 2011 |
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2012 |
Coadministration of 5% glucose solution has a decrease in bendamustine-related vascular pain grade.
Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Glucose; Humans; Lymphoma, Follicular; Male; Middle Aged; Nitrogen Mustard Compounds; Pain | 2012 |
[II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2012 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Burkitt Lymphoma; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cladribine; Complement Activation; Complement System Proteins; Cysteine Proteinase Inhibitors; Doxorubicin; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Rabbits; Rituximab; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |